Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
01
09
2022
accepted:
23
03
2023
revised:
16
03
2023
pmc-release:
07
04
2024
medline:
7
6
2023
pubmed:
8
4
2023
entrez:
7
4
2023
Statut:
ppublish
Résumé
Only a subset of gastric cancer (GC) patients with stage II-III benefits from chemotherapy after surgery. Tumour infiltrating lymphocytes per area (TIL density) has been suggested as a potential predictive biomarker of chemotherapy benefit. We quantified TIL density in digital images of haematoxylin-eosin (HE) stained tissue using deep learning in 307 GC patients of the Yonsei Cancer Center (YCC) (193 surgery+adjuvant chemotherapy [S + C], 114 surgery alone [S]) and 629 CLASSIC trial GC patients (325 S + C and 304 S). The relationship between TIL density, disease-free survival (DFS) and clinicopathological variables was analysed. YCC S patients and CLASSIC S patients with high TIL density had longer DFS than S patients with low TIL density (P = 0.007 and P = 0.013, respectively). Furthermore, CLASSIC patients with low TIL density had longer DFS if treated with S + C compared to S (P = 0.003). No significant relationship of TIL density with other clinicopathological variables was found. This is the first study to suggest TIL density automatically quantified in routine HE stained tissue sections as a novel, clinically useful biomarker to identify stage II-III GC patients deriving benefit from adjuvant chemotherapy. Validation of our results in a prospective study is warranted.
Sections du résumé
BACKGROUND
Only a subset of gastric cancer (GC) patients with stage II-III benefits from chemotherapy after surgery. Tumour infiltrating lymphocytes per area (TIL density) has been suggested as a potential predictive biomarker of chemotherapy benefit.
METHODS
We quantified TIL density in digital images of haematoxylin-eosin (HE) stained tissue using deep learning in 307 GC patients of the Yonsei Cancer Center (YCC) (193 surgery+adjuvant chemotherapy [S + C], 114 surgery alone [S]) and 629 CLASSIC trial GC patients (325 S + C and 304 S). The relationship between TIL density, disease-free survival (DFS) and clinicopathological variables was analysed.
RESULTS
YCC S patients and CLASSIC S patients with high TIL density had longer DFS than S patients with low TIL density (P = 0.007 and P = 0.013, respectively). Furthermore, CLASSIC patients with low TIL density had longer DFS if treated with S + C compared to S (P = 0.003). No significant relationship of TIL density with other clinicopathological variables was found.
CONCLUSION
This is the first study to suggest TIL density automatically quantified in routine HE stained tissue sections as a novel, clinically useful biomarker to identify stage II-III GC patients deriving benefit from adjuvant chemotherapy. Validation of our results in a prospective study is warranted.
Identifiants
pubmed: 37029200
doi: 10.1038/s41416-023-02257-3
pii: 10.1038/s41416-023-02257-3
pmc: PMC10241786
doi:
Substances chimiques
Biomarkers
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2318-2325Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Front Immunol. 2019 Jan 29;10:71
pubmed: 30761139
J Clin Oncol. 2021 Sep 10;39(26):2903-2913
pubmed: 34133211
Cancer Med. 2021 Jul;10(14):4790-4795
pubmed: 34080777
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
APMIS. 2018 Oct;126(10):814-821
pubmed: 30264431
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Ann Diagn Pathol. 2018 Aug;35:77-79
pubmed: 29886396
Lancet Oncol. 2021 Aug;22(8):1081-1092
pubmed: 34252374
Lancet Oncol. 2014 Nov;15(12):1389-96
pubmed: 25439693
Ann Surg. 2019 Aug;270(2):309-316
pubmed: 29727332
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
Lancet Oncol. 2016 Jun;17(6):717-726
pubmed: 27157491
Gastric Cancer. 2021 Jan;24(1):1-21
pubmed: 32060757
Lancet Oncol. 2018 May;19(5):629-638
pubmed: 29567071
Front Immunol. 2021 Jul 01;12:692859
pubmed: 34276684
Lancet Oncol. 2014 Jul;15(8):886-93
pubmed: 24954805
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
JAMA Netw Open. 2022 Feb 01;5(2):e220426
pubmed: 35226081
Cancer Sci. 2019 Nov;110(11):3405-3414
pubmed: 31495054
Sci Rep. 2018 May 10;8(1):7485
pubmed: 29748589
In Vivo. 2018 Jan-Feb;32(1):151-158
pubmed: 29275313
Medicine (Baltimore). 2018 Jul;97(27):e11387
pubmed: 29979429
Gut. 2015 Nov;64(11):1721-31
pubmed: 25385008
BMJ Open. 2021 Jan 31;11(1):e044163
pubmed: 33518526
Oncotarget. 2017 Feb 7;8(6):9608-9616
pubmed: 28030810
Medicine (Baltimore). 2018 Aug;97(32):e11769
pubmed: 30095632
J Clin Oncol. 2011 Nov 20;29(33):4387-93
pubmed: 22010012
Ann Oncol. 2016 Mar;27(3):494-501
pubmed: 26673353
J Clin Oncol. 2015 Mar 20;33(9):983-91
pubmed: 25534375
Pathology. 2017 Oct;49(6):589-595
pubmed: 28843920
Nat Methods. 2019 Apr;16(4):351
pubmed: 30804552
J Clin Oncol. 2016 Apr 10;34(11):1223-30
pubmed: 26834066